Evidence map›Paper›PMID 28224273›Full record

ArticleInternational journal of hematology2017

Over-expression of miR-196b-5p is significantly associated with the progression of myelodysplastic syndrome.

Jing Wen, Ying Huang, Hongying Li, Xupai Zhang, Peng Cheng, Donghong Deng, Zhigang Peng, Jun Luo, Weihua Zhao, Yongrong Lai and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Prognostic Markers of Myelodysplastic Syndromes.Medicina (Kaunas, Lithuania) · 2020
    Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jing WenHematology Department, First Affiliated Hospital, Guangxi Medical University, ShuangYong Road 6, Nanning, 530021, Guangxi, China.
Ying HuangHematology Department, First Affiliated Hospital, Guangxi Medical University, ShuangYong Road 6, Nanning, 530021, Guangxi, China.
Hongying LiHematology Department, First People's Hospital of Nanning, Nanning, 530022, Guangxi, China.
Xupai ZhangHematology Department, First Affiliated Hospital, Guangxi Medical University, ShuangYong Road 6, Nanning, 530021, Guangxi, China.
Peng ChengHematology Department, First Affiliated Hospital, Guangxi Medical University, ShuangYong Road 6, Nanning, 530021, Guangxi, China.
Donghong DengHematology Department, First Affiliated Hospital, Guangxi Medical University, ShuangYong Road 6, Nanning, 530021, Guangxi, China.
Zhigang PengHematology Department, First Affiliated Hospital, Guangxi Medical University, ShuangYong Road 6, Nanning, 530021, Guangxi, China.
Jun LuoHematology Department, First Affiliated Hospital, Guangxi Medical University, ShuangYong Road 6, Nanning, 530021, Guangxi, China.
Weihua ZhaoHematology Department, First Affiliated Hospital, Guangxi Medical University, ShuangYong Road 6, Nanning, 530021, Guangxi, China.
Yongrong LaiHematology Department, First Affiliated Hospital, Guangxi Medical University, ShuangYong Road 6, Nanning, 530021, Guangxi, China.
Zhenfang LiuHematology Department, First Affiliated Hospital, Guangxi Medical University, ShuangYong Road 6, Nanning, 530021, Guangxi, China. Liuliuzhenfang@126.com.
Guangxi Medical University · CNFirst Affiliated Hospital of GuangXi Medical University · CNFirst People's Hospital of Nanning · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myelodysplastic syndrome (MDS) is a clonal stem cell disorder characterized by ineffective hematopoiesis with a high risk of transformation to acute myeloid leukemia (AML). miRNAs function as tumor suppressors and oncogenes in various cancers and regulate the differentiation potential of hematopoietic stem and progenitor cells (HSPCs). It has been suggested that miRNAs may play an important role in progression of MDS. We analyzed bone marrow samples collected from MDS patients according to different risk stratification indicated by the International Prognostic Scoring System (IPSS). We demonstrated that miR-196b-5p was up-regulated in intermediate II and higher groups, and in secondary AML (s-AML) patients in particular (P < 0.01) compared with healthy controls, suggesting that the higher expression levels are associated with increased risk of the development of MDS. We observed changes in proliferation and apoptosis in MDS-L cells following transfection with miR-196-5p mimics or inhibitors. After up-regulating the expression of miR-196b-5p, proliferation of MDS-L cells was up-regulated, whereas apoptosis was down-regulated (P < 0.05). In contrast, down-regulation of miR-196b-5p expression decreased cell proliferation and increased apoptosis (P < 0.05). We concluded that over-expression of miR-196b-5p may be closely associated with the risk of transformation to leukemia in MDS patients.

Indexed as

ApoptosisCell ProliferationDown-RegulationUp-RegulationAdultAgedAged, 80 and overFemaleHumansMaleMicroRNAsMiddle AgedMyelodysplastic SyndromesMicroRNAsMIRN196 microRNA, humanLeukemiaMicroRNAmiR-196bMyelodysplastic syndromes

Identifiers

PMID28224273
OpenAlexW2591333313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.